AKUMS Akums Drugs Q4 FY25 results (Jan–Mar 2025) and concall
Akums Drugs reported a mixed Q4 and FY25, with flat full-year revenue but improved PAT. The company secured a significant EUR200 million CDMO contract and increased R&D investments, driving new product launches. However, API and trade generic businesses remain loss-making, and API price volatility continues to be a headwind. Management is focused on consolidating loss-making segments and expanding global CDMO presence.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 328 | 337 | 329 |
| EBITDA | 43 | 34 | 18 |
| Net profit | 50 | 41 | 28 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
